Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)
- D. BarattiAffiliated withDepartment of Surgery, National Cancer Institute
- , S. KusamuraAffiliated withDepartment of Surgery, National Cancer Institute
- , D. NonakaAffiliated withDepartment of Pathology, National Cancer Institute
- , G. D. OlivaAffiliated withDepartment of Surgery, National Cancer Institute
- , B. LaterzaAffiliated withDepartment of Surgery, National Cancer Institute
- , M. DeracoAffiliated withDepartment of Surgery, National Cancer Institute Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Multicystic peritoneal mesothelioma (MPM) and well-differentiated papillary peritoneal mesothelioma (WDPPM) are exceedingly uncommon lesions with uncertain malignant potential and no uniform treatment strategy. The aim of the current study was to review our experience with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in these clinical settings.
Four women with MPM and eight with WDPPM underwent 13 procedures of cytoreduction and close-abdomen HIPEC with cis-platin and doxorubicin. Seven patients had recurrent disease after previous debulking (one operation in five patients, two in one, four in one). Potential clinicopathological prognostic factors were assessed.
Optimal cytoreduction (residual tumor nodules ≤2.5 mm) was performed in 12 of 13 procedures. Median follow-up was 27 months (range 6–94). One grade 4 postoperative complication (NCI/CTCAE v.3.0) and no operative mortalities occurred. One patient underwent the procedure twice due to locoregional MPM recurrence. Transition of typical WDPPM to malignant biphasic mesothelioma was documented in one patient who died of disease progression following incomplete cytoreduction and HIPEC. Following multimodality treatment, 5-year overall and progression-free survival were 90.0% (standard error = 9.0) and 79.7% (11.9), respectively. Progression-free survival following previous debulking surgery (median 24 months; range 2–87) was statistically worse (P = .0156). Incomplete cytoreduction and poor performance status correlated to both reduced overall and progression-free survival after cytoreduction and HIPEC.
MPM and WDPPM are borderline tumors capable of transformation into potentially lethal processes. Definitive tumor eradication by means of cytoreduction and HIPEC seems more effective than debulking surgery in preventing disease recurrence or transition to aggressive malignancies.
KeywordsMulticystic peritoneal mesothelioma Well-differentiated papillary peritoneal mesothelioma Peritonectomy Hyperthermic intraperitoneal chemotherapy; HIPEC
- Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)
Annals of Surgical Oncology
Volume 14, Issue 10 , pp 2790-2797
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Multicystic peritoneal mesothelioma
- Well-differentiated papillary peritoneal mesothelioma
- Hyperthermic intraperitoneal chemotherapy; HIPEC
- Industry Sectors